在阿尔茨海默氏症疾病中使用金色化物的网络药理方法的机制
Shan He1, Junhe Shi2, Hua Chai3
1Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
人参中的化合物金色化物,通过向关键的病理机制,在治疗阿尔茨海默病 (AD) 方面表现有前途. 对金色化物的进一步研究可能会导致新的AD疗法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,有效治疗方法有限.
- 目前的AD药物提供症状缓解,但不会改变疾病的进展,并可能导致副作用.
- 来自人参的金色化物表现出与AD病理相关的神经保护性质.
研究的目的:
- 审查在阿尔茨海默病中使用金氏的治疗潜力和机制.
- 为未来的研究和临床应用提供洞察力.
主要方法:
- 在多个数据库中进行文献搜索 (截至2023年4月) 寻找关于人参和AD的研究.
- 应用网络药理和生物信息学来预测治疗效果和机制.
- 从检索的研究和计算分析中综合发现.
主要成果:
- 银化物对阿尔茨海默氏症表现出多方面的治疗作用.
- 这些活动包括减少粉样β (Aβ) 沉积和陶过酸化.
- 银化物还调节胆固醇系统,氧化应激,平衡,炎症和亡.
结论:
- 氏体对阿尔茨海默病具有显著的治疗潜力.
- 它们的多样化作用机制为新型AD药物开发提供了有希望的途径.
- 将网络药理与现有研究结合起来,可以支持人参化物在阿尔茨海默病的临床应用.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12:34Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
